Overview of anticonvulsant therapy in full-term and premature neonates
M. A. Ivzhits,
S. K. Zyryanov,
G. V. Rodoman,
I. B. Bondareva,
S. V. Dumova,
O. A. Babak,
M. S. Chenkurov,
G. A. Putsman https://doi.org/10.17650/2073-8803-2020-15-2-42-54
Abstract
Convulsions in full-term and especially in premature newborns are observable pathologies. Selection of anticonvulsant therapy is very difficult: newborns have particular pharmacokinetics of drugs, insufficient data on doses and therapeutic concentrations of anticonvulsants in the blood (premature infants mainly). This article is an overview, with an emphasis on the features of dosing and pharmacokinetics of anticonvulsants in term and preterm infants.
About the Authors
M. A. Ivzhits
City Clinical Hospital No. 24, Moscow Healthcare Department; Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
10 Pistsovaya St., Moscow 127015
6 Miklukho-Maklaya St., Moscow 117198
S. K. Zyryanov
City Clinical Hospital No. 24, Moscow Healthcare Department; Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
10 Pistsovaya St., Moscow 127015
6 Miklukho-Maklaya St., Moscow 117198
G. V. Rodoman
City Clinical Hospital No. 24, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
10 Pistsovaya St., Moscow 127015
1 Ostrovityanova St., Moscow 117997
I. B. Bondareva
Peoples’ Friendship University of Russia
Russian Federation
6 Miklukho-Maklaya St., Moscow 117198
Russian Federation
6 Miklukho-Maklaya St., Moscow 117198
S. V. Dumova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Perinatal Center, City Clinical Hospital No. 24, Moscow Healthcare Department
Russian Federation
Russian Federation
1 Ostrovityanova St., Moscow 117997
39 4 th Vyatskiy Per., Moscow 127287
O. A. Babak
Perinatal Center, City Clinical Hospital No. 24, Moscow Healthcare Department
Russian Federation
39 4 th Vyatskiy Per., Moscow 127287
Russian Federation
39 4 th Vyatskiy Per., Moscow 127287
M. S. Chenkurov
Peoples’ Friendship University of Russia
Russian Federation
6 Miklukho-Maklaya St., Moscow 117198
Russian Federation
6 Miklukho-Maklaya St., Moscow 117198
G. A. Putsman
Peoples’ Friendship University of Russia
Russian Federation
6 Miklukho-Maklaya St., Moscow 117198
Russian Federation
6 Miklukho-Maklaya St., Moscow 117198
References
1. Айкарди Ж., Бакс М., Гиллберг К. Заболевания нервной системы у детей. Пер. с англ. Под ред. А.А. Скоромца. М.: БИНОМ, 2013. 1036 c. [Aicardi J., Bax M., Gillberg C. Diseases of the nervous system in childhood. Transl. from Engl. by A.A. Skoromets. Moscow: BINOM, 2013. 1036 p. (In Russ.)].
2. Государственный реестр лекарственных средств. Инструкция к препарату Габапентин. [State register of medicines. Gabapentin package insert. (In Russ.)].
3. Сергиенко В.И., Джелифф Р., Бондарева И.Б. Прикладная фармакокинетика: основные положения и клиническое применение. М.: Издательство РАМН, 2003. [Sergienko V.I., Jeliff R., Bondareva I.B. Applied pharmacokinetics: main provisions and clinical application. Moscow: Izdatelstvo RAMN, 2003. (In Russ.)].
4. Abend N.S., Gutierrez-Colina A.M., Monk H.M. et al. Levetiracetam for Treatment of Neonatal Seizures. J Child Neurol 2011;26(4):465–70. DOI: 10.1177/0883073810384263. PMID: 21233461.
5. Alfonso I., Alvarez L.A., Gilman J. et al. Intravenous valproate dosing in neonates. J Child Neurol 2000;15(12):827–9. DOI: 10.1177/088307380001501216. PMID:11198504
6. Bassan H., Bental Y., Shany E. et al. Neonatal seizures: dilemmas in workup and management. Pediatr Neurol 2008;38(6):415–21. DOI: 10.1016/j.pediatrneurol.2008.03.003.
7. Berardi D., Clemente R., Finn B.C. et al. Not to forget interaction between meropenem and valproic acid. Rev Med Chil 2014;142(3):400–1. DOI: 10.4067/S0034-98872014000300019.
8. Bűdi T., Tóth K., Nagy A. et al. Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia 2015;56(6):849–55. DOI: 10.1111/epi.13011.
9. Cloyd J.C., Birnbaum A.K., Kreil R.L. Pharmacokinetics in infancy, childhood, and adolescence. The treatment of epilepsy: Principles and practice. Ed. by E. Wyllie. Baltimore, Philadelphia, London, Paris, Bangkok, Buenos Airies, Munich, Sydney, Tokyo, Wroclaw, 1997. Pp. 737–747.
10. Donovan M.D., Griffin B.T., Kharoshankaya L. et al. Pharmacotherapy for neonatal seizures: current knowledge and future perspectives. Drugs 2016;76(6):647–61. DOI: 10.1007/s40265-016-0554-7.
11. Filippi L., la Marca G., Fiorini P. et al. Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy. Epilepsia 2009;50(11):2355–61. DOI: 10.1111/j.1528-1167.2009.02302.x.
12. Glass H.C., Poulin C., Shevell M.I. Topiramate for the treatment of neonatal seizures. Pediatr Neurol 2011;44(6):439–42. DOI: 10.1016/j.pediatrneurol.2011.01.006.
13. Glass H.C., Kan J., Bonifacio S.L. et al. Neonatal seizures: treatment practices among term and preterm infants. Pediatr Neurol 2012;46(2):111–5. DOI: 10.1016/j.pediatrneurol.2011.11.006.
14. Glauser T., Ben-Menachem E., Bourgeois B. et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54(3):551–63. DOI: 10.1111/epi.12074.
15. Hellstrom-Westas L., Boylan G., Agren J. Systematic review of neonatal seizure management strategies provides guidance on anti-epileptic treatment. Acta Paediatr 2015;104(2):123–9. DOI: 10.1111/apa.12812.
16. Hellwig T.R., Onisk M.L., Chapman B.A. Potential interaction between valproic acid and doripenem. Curr Drug Saf 2011;6(1):54–8.
17. Jae W.S., Yun S.J., Kyungsoo P. et al. Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures. Korean J Pediatr 2017;60(2):50–4. DOI: 10.3345/kjp.2017.60.2.50.
18. Khan O., Cipriani C., Wright C. et al. Role of intravenous levetiracetam for acute seizure management in preterm neonates. Pediatr Neurol 2013;49(5):340–3. DOI: 10.1016/j.pediatrneurol.2013.05.008.
19. Kohelet D., Shochat R., Lusky A. et al. Risk Factors for neonatal seizures in very low birthweight infants. J Child Neurol 2004;19:123–8. DOI: 10.1177/08830738040190020701.
20. Merhar S.L., Schibler K.R., Sherwin C.M. et al. Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr 2011;159(1):152–4. DOI: 10.1016/j.jpeds.2011.03.057.
21. Miranda Herrero M.C., Alcaraz Romero A.J., Escudero Vilaplana V. et al. Pharmacological interaction between valproic acid and carbapenem: what about levels in pediatrics? Eur J Paediatr Neurol 2015;19(2):155–61. DOI: 10.1016/j.ejpn.2014.12.010.
22. Mruk A.L., Garlitz K.L., Leung N.R. Levetiracetam in neonatal seizures: a review. J Pediatr Pharmacol Ther 2015;20(2):76–89. DOI: 10.5863/1551-6776-20.2.76.
23. Pacifici G.M. Clinical pharmacology of phenobarbital in neonates: effects, metabolism and pharmacokinetics. Curr Pediatr Rev 2016;12(1):48–54.
24. Patsalos P.N., Berry D.J., Bourgeois B.F. et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia 2008;49(7):1239–76. DOI: 10.1111/j.1528-1167.2008.01561.x.
25. Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2(6):347–56.
26. Panayiotopoulos C.P., Chrysostomos P., International League against Epilepsy. The epilepsies: seizures, syndromes and management: based on the ILAE classifications and practice parameter guidelines. Bladon Medical Publishing, 2005.
27. Pina-Garza J.E., Nordli D.R.Jr., Rating D. et al. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia 2009;50(5):1141–9. DOI: 10.1111/j.1528-1167.2008. 01981.x.
28. Pressler R.M., Mangum B. Newly emerging therapies for neonatal seizures. Semin Fetal Neonatal Med 2013;18(4):216–23. DOI: 10.1016/j.siny.2013.04.005.
29. Ronen G.M., Penney S. The epidemiology of clinical neonatal seizures in Newfoundland, Canada: a five-year cohort study. Neurology 1995;38:518–9.
30. Saliba R.M., Annegers J.F., Mizrahi E.M. Incidence of clinical neonatal seizures. Epilepsia 1996;37:13.
31. Sandoval K.A. Infectious disease and pharmacology neonatology questions and controversies. Chapter 17. In: Antiepileptic Drug Therapy in Neonates. 2019. Pp. 207–226.
32. Scher M.S. Neonatal seizure classification: A fetal perspective concerning childhood epilepsy. Epilepsy Res 2006;70:41–57. DOI: 10.1016/j.eplepsyres.2005.11.020.
33. Singh B., Singh P., al Hifzi I. et al. Treatment of neonatal seizures with carbamazepine. J Child Neurol 1996;11(5): 378–82. DOI: 10.1177/088307389601100506.
34. Shoemaker M.T., Rotenberg J.S. Levetiracetam for the treatment of neonatal seizures. J Child Neurol 2007;22(1):95–9. DOI: 10.1177/0883073807299973.
35. Steinberg A., Shalev R.S., Amir N. Valproic acid in neonatal status convulsivus. Brain Dev 1986;8(3):278–9.
36. Tebedge E.W. Moving on up? Phenobarbital vs. levetiracetam for first line treatment of neonatal seizures. The University of Texas at Austin College of Pharmacy, UT Health San Antonio, 2018. 18 p.
37. Tulloch J.K., Carr R.R., Ensom M.H. A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures. J Pediatr Pharmacol Ther 2012;17(1):31–44. DOI: 10.5863/1551-6776-17.1.31.
38. Van Rooij L.G., van den Broek M.P., Rademaker C.M. et al. Clinical management of seizures in newborns: diagnosis and treatment. Paediatr Drugs 2013;15(1):9–18. DOI: 10.1007/s40272-012-0005-1.
39. Vesoulis Z.A., Mathur A.M. Advances in management of neonatal seizures. Indian J Pediatr 2014;81(6):592–8. DOI: 10.1007/s12098-014-1457-9.
40. WHO Guidelines Approved by the Guidelines Review Committee. Guidelines on Neonatal Seizures. Geneva: World Health Organization, 2011.
41. Wu C.C., Pai T.Y., Hsiao F.Y. et al. The effect of different carbapenem antibiotics (ertapenem, imipenem/ cilastatin, and meropenem) on serum valproic acid concentrations. Ther Drug Monit 2016;38(5):587–92. DOI: 10.1097/FTD.0000000000000316.
Review
For citations:
Ivzhits M.A., Zyryanov S.K., Rodoman G.V., Bondareva I.B., Dumova S.V., Babak O.A., Chenkurov M.S., Putsman G.A. Overview of anticonvulsant therapy in full-term and premature neonates. Russian Journal of Child Neurology. 2020;15(2):42-54. (In Russ.) https://doi.org/10.17650/2073-8803-2020-15-2-42-54
Views:
1655
Email this article 